Therapeutic management of bone metastasis in prostate cancer: an update

References

• [cited 2016 Sep 21]. Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042801.pdf.
   Google Scholar
• Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002;52(3):154–179.
   PubMed Web of Science ®Google Scholar
• Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(14):1652–1659.
   PubMed Web of Science ®Google Scholar
• Costa L, Badia X, Chow E, et al. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2008;16(8):879–889.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Garrett-Mayer ES, Yang Y-CO, et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(21):6396–6403.
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2005;16(4):579–584.
   PubMed Web of Science ®Google Scholar
• Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care. 2008;14(5):317–322.
   PubMed Web of Science ®Google Scholar
• Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(1):20–27.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(20 Pt 2):6243s–6249s.
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Body J-J, Brandi M-L, et al. Cancer-associated bone disease. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2013;24(12):2929–2953.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520.
   PubMed Web of Science ®Google Scholar
• El-Amm J, Aragon-Ching JB. The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2013;5(1):25–40.
   PubMed Web of Science ®Google Scholar
• El-Amm J, Freeman A, Patel N, et al. Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer. 2013;2013:210686.
   PubMedGoogle Scholar
• Nonhormone therapy for metastatic castration-resistant prostate cancer: chemotherapy, bone-targeted treatments, and others [Internet]. J Clin Oncol. Available from: http://meetinglibrary.asco.org/content/29-132
   Google Scholar
• Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(13):2918–2925.
   PubMed Web of Science ®Google Scholar
• Smith MR, Cook R, Lee K-A, et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011;117(10):2077–2085.
   PubMed Web of Science ®Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–1192.
   PubMed Web of Science ®Google Scholar
• Bader P, Echtle D, Fonteyne V, et al. Prostate cancer pain management: EAU guidelines on pain management. World J Urol. 2012;30(5):677–686.
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Jensen AØ, Jacobsen JB, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162–167.
   PubMed Web of Science ®Google Scholar
• Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis. 2011;14(2):177–183.
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–882.
   PubMed Web of Science ®Google Scholar
• Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000;88(12 Suppl):2989–2994.
   PubMedGoogle Scholar
• Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100(5):892–899.
   PubMed Web of Science ®Google Scholar
• Rigaud J, Tiguert R, Le Normand L, et al. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol. 2002;168(4 Pt 1):1423–1426.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Garrett-Mayer E, de Wit R, et al. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(1):203–211.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Massard C, Smith M, et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol. 2015;68(1):42–50.
   PubMed Web of Science ®Google Scholar
• Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97(1):59–69.
   PubMed Web of Science ®Google Scholar
• Som A, Tu S-M, Liu J, et al. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer. 2012;107(9):1547–1553.
   PubMed Web of Science ®Google Scholar
• Berruti A, Tucci M, Mosca A, et al. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer. 2005;93(6):633–638.
   PubMed Web of Science ®Google Scholar
• Briganti A, Suardi N, Gallina A, et al. Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev. 2014;40(1):3–11.
   PubMed Web of Science ®Google Scholar
• Sartor O, Eisenberger M, Kattan MW, et al. Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist. 2013;18(5):549–557.
   PubMed Web of Science ®Google Scholar
• Lecouvet FE, Geukens D, Stainier A, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(22):3281–3287.
   PubMed Web of Science ®Google Scholar
• Yu EY, Miller K, Nelson J, et al. Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. J Urol. 2012;188(1):103–109.
   PubMed Web of Science ®Google Scholar
• Beauregard J-M, Pouliot F. New developments in the imaging of metastatic prostate cancer. Curr Opin Support Palliat Care. 2014;8(3):265–270.
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(12):1402–1418.
   PubMed Web of Science ®Google Scholar
• Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem. 2004;91(4):718–729.
   PubMed Web of Science ®Google Scholar
• Dushyanthen S, Cossigny DAF, Quan GMY. The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer. Cancer Growth Metastasis. 2013;6:61–80.
   PubMedGoogle Scholar
• Vignani F, Bertaglia V, Buttigliero C, et al. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treat Rev. 2016;44:61–73.
   PubMed Web of Science ®Google Scholar
• Gartrell BA, Saad F. Managing bone metastases and reducing skeletal related events in prostate cancer. Nat Rev Clin Oncol. 2014;11(6):335–345.
   PubMed Web of Science ®Google Scholar
• Bonci D, Coppola V, Patrizii M, et al. A microRNA code for prostate cancer metastasis. Oncogene. 2016;35(9):1180–1192.
   PubMed Web of Science ®Google Scholar
• Fu Q, Liu X, Liu Y, et al. MicroRNA-335 and −543 suppress bone metastasis in prostate cancer via targeting endothelial nitric oxide synthase. Int J Mol Med. 2015;36(5):1417–1425.
   PubMed Web of Science ®Google Scholar
• Ge C, Zhao G, Li Y, et al. Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. Oncogene. 2016;35(3):366–376.
   PubMed Web of Science ®Google Scholar
• Miftakhova R, Hedblom A, Semenas J, et al. Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow. Cancer Res. 2016;76:2453–2464.
   PubMed Web of Science ®Google Scholar
• Yan J, Ojo D, Kapoor A, et al. Neural cell adhesion protein CNTN1 promotes the metastatic progression of prostate cancer. Cancer Res. 2016;76(6):1603–1614.
   PubMed Web of Science ®Google Scholar
• Cai B, Nickman NA, Gaffney DK. The role of palliative external beam radiation therapy in boney metastases pain management. J Pain Palliat Care Pharmacother. 2013;27(1):28–34.
   PubMedGoogle Scholar
• McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2005;(2):CD005180. doi:10.1002/14651858.CD005180.
   Web of Science ®Google Scholar
• Di Lorenzo G, Autorino R, Ciardiello F, et al. External beam radiotherapy in bone metastatic prostate cancer: impact on patients’ pain relief and quality of life. Oncol Rep. 2003;10(2):399–404.
   PubMed Web of Science ®Google Scholar
• Johnstone C, Lutz ST. External beam radiotherapy and bone metastases. Ann Palliat Med. 2014;3(2):114–122.
   PubMedGoogle Scholar
• Goyal J, Antonarakis ES. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett. 2012;323(2):135–146.
   PubMed Web of Science ®Google Scholar
• Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–945.
   PubMed Web of Science ®Google Scholar
• Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer. 2000;88(12 Suppl):2934–2939.
   PubMedGoogle Scholar
• Roqué I Figuls M, Martinez-Zapata MJ, Scott-Brown M, et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2011;(7):CD003347.
   PubMed Web of Science ®Google Scholar
• Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of RTOG 0517 [Internet]. J Clin Oncol. Available from: http://meetinglibrary.asco.org/content/99922-114
   Web of Science ®Google Scholar
• Bilen MA, Johnson MM, Mathew P, et al. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015;121(1):69–76.
   PubMed Web of Science ®Google Scholar
• McNicol ED, Strassels S, Goudas L, et al. WITHDRAWN: NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2015;7:CD005180.
   PubMed Web of Science ®Google Scholar
• Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–692.
   PubMed Web of Science ®Google Scholar
• Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer. 2004;11(2):207–224.
   PubMed Web of Science ®Google Scholar
• Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345(13):948–955.
   PubMed Web of Science ®Google Scholar
• Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2008–2012;169(6):2003.
   Google Scholar
• Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–1468.
   PubMed Web of Science ®Google Scholar
• James ND, Pirrie SJ, Pope AM, et al. Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the TRAPEZE randomized clinical trial. JAMA Oncol. 2016;2(4):493–499.
   PubMed Web of Science ®Google Scholar
• Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(11):1143–1150.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet Lond Engl. 2016;387(10024):1163–1177.
   PubMed Web of Science ®Google Scholar
• Wirth M, Tammela T, Cicalese V, et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol. 2015;67(3):482–491.
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–342.
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–755.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet Lond Engl. 2011;377(9768):813–822.
   PubMed Web of Science ®Google Scholar
• Smith MR, Coleman RE, Klotz L, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015;26(2):368–374.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet Lond Engl. 2012;379(9810):39–46.
   PubMed Web of Science ®Google Scholar
• Lipton A, Fizazi K, Stopeck AT, et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer Oxf Engl 1990. 2016;53:75–83.
   PubMed Web of Science ®Google Scholar
• Lipton A, Smith MR, Fizazi K, et al. Changes in bone turnover marker levels and clinical outcomes in patients with advanced cancer and bone metastases treated with bone antiresorptive agents. Clin Cancer Res Off J Am Assoc Cancer Res. 2016.
   Google Scholar
• Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(2):242–245.
   PubMed Web of Science ®Google Scholar
• Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–158.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet Lond Engl. 2010;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(9):2402–2408.
   PubMed Web of Science ®Google Scholar
• Nussbaum N, George DJ, Abernethy AP, et al. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis. 2016;19(2):111–121.
   PubMed Web of Science ®Google Scholar
• Bahl A, Masson S, Malik Z, et al. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU Int. 2015;116(6):880–887.
   PubMed Web of Science ®Google Scholar
• Barrie SE, Potter GA, Goddard PM, et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol. 1994;50(5–6):267–273.
   PubMed Web of Science ®Google Scholar
• Jarman M, Barrie SE, Llera JM. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem. 1998;41(27):5375–5381.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 1995–2005;364(21):2011.
   Google Scholar
• Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13(12):1210–1217.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate cancer. N Engl J Med. 2013;368(15):1458–1459.
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014;66(5):815–825.
   PubMed Web of Science ®Google Scholar
• Saad F, Shore N, Van Poppel H, et al. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015;68(4):570–577.
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–790.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Saad F, de Bono J, Shore N, et al. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. Eur Urol. 2015;67(2):223–230.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• Loriot Y, Miller K, Sternberg CN, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015;16(5):509–521.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223.
   PubMed Web of Science ®Google Scholar
• Hoskin P, Sartor O, O’Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–1406.
   PubMed Web of Science ®Google Scholar
• Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738–746.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Cislo P, Sartor O, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2016;27(5):868–874.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer Oxf Engl 1990. 2012;48(5):678–686.
   PubMed Web of Science ®Google Scholar
• Michalski JM, Parker C, Sartor O, et al. Impact of prior docetaxel, extent of disease (EOD), and prior bisphosphonates (Bp) on hematologic (Heme) safety of radium-223 dichloride (Ra-223) from ALSYMPCA. Int J Radiat Oncol Biol Phys. 2014;90(1):S441–S442.
   Google Scholar
• Sartor O, Hoskin P, Coleman RE, et al. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate. 2016;76(10):905–916.
   PubMed Web of Science ®Google Scholar
• Dan TD, Eldredge-Hindy HB, Hoffman-Censits J, et al. Hematologic toxicity of concurrent administration of radium-223 and next-generation antiandrogen therapies. Am J Clin Oncol. 2015;1.
   PubMedGoogle Scholar
• Radium-223 in an international early access program (EAP): effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRCP) patients [Internet]. J Clin Oncol. Available from: http://meetinglibrary.asco.org/content/147884-156
   Web of Science ®Google Scholar
• Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP) [Internet]. J Clin Oncol. Available from: http://meetinglibrary.asco.org/content/141865-159
   Web of Science ®Google Scholar
• Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine–Dendreon. Drugs RD. 2006;7(3):197–201.
   PubMedGoogle Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Paszulewicz A, Holko P, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci AMS. 2012;8(5):767–775.
   PubMed Web of Science ®Google Scholar
• Cost to NHS of providing sipuleucel-T too high to be recommended in draft guidance |Press and media |News |NICE [Internet]. Available from: https://www.nice.org.uk/news/press-and-media/sipuleucel-t-cost-too-high-for-nhs-draft-guidance.
   Google Scholar
• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–176.
   PubMed Web of Science ®Google Scholar
• Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9(Suppl 4):28–37.
   PubMed Web of Science ®Google Scholar
• Body J-J, Bone HG, de Boer RH, et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer Oxf Engl 1990. 1812–1821;51(13):2015.
   Google Scholar
• Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Cancer Netw JNCCN. 2010;8(2):162–200.
   PubMed Web of Science ®Google Scholar
• De Maeseneer DJ, Van Praet C, Lumen N, et al. Battling resistance mechanisms in antihormonal prostate cancer treatment: novel agents and combinations. Urol Oncol. 2015;33(7):310–321.
   PubMed Web of Science ®Google Scholar
• Bastos DA, Antonarakis ES. Galeterone for the treatment of advanced prostate cancer: the evidence to date. Drug Des Devel Ther. 2016;10:2289–2297.
   PubMed Web of Science ®Google Scholar
• Montgomery B, Eisenberger MA, Rettig MB, et al. Androgen receptor modulation optimized for response (ARMOR) phase I and II studies: galeterone for the treatment of castration-resistant prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(6):1356–1363.
   PubMed Web of Science ®Google Scholar
• Dellis A, Papatsoris AG, Phase I. II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer. Expert Opin Investig Drugs. 2016;25(6):697–707.
   PubMed Web of Science ®Google Scholar
• Karantanos T, Evans CP, Tombal B, et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015;67(3):470–479.
   PubMed Web of Science ®Google Scholar